SOHO 2023 | Recent advances in the treatment of LR-MDS: COMMANDS and IMerge trial data
Valeria Santini, MD, University of Florence, Florence, Italy, discusses exciting breakthroughs made in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) based on findings from two recent clinical trials. Prof. Santini briefly summarizes the COMMANDS trial (NCT03682536), which led to the approval of luspatercept for the treatment of patients in the frontline setting. Prof. Santini also discusses the IMerge trial (NCT02598661), which demonstrated that imetelstat can effectively improve transfusion independence in patients with LR-MDS, as well as produce a disease-modifying effect. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
